**Core tip:** Bibliometrics was used to quantitatively analyze top 100 cited articles from the database of the Science Citation Index Expanded to reveal the global publication trends about nonalcoholic fatty liver disease (NAFLD). This study is the first global look at the history and current situation of NAFLD research to assess the performances of leading countries/territories and institutes and research hotspots of this disease. The performances and research hotspots are related to the potential pathogenesis of NAFLD. Incidence and prevalence as well as treatment progress for NAFLD were systematically reviewed, and their relationships with global performances results were also discussed.

INTRODUCTION
============

Nonalcoholic fatty liver disease (NAFLD) is defined by liver fat deposition with a concentration of hepatic triglycerides exceeding 5% of liver weight in the absence of excessive alcohol intake. NAFLD is an umbrella term used to describe a histological spectrum ranging from simple steatosis to nonalcoholic steatohepatitis (NASH). NASH is virtually indistinguishable histologically from alcoholic steatohepatitis, which is designated the disease with inflammation and liver cell injury in some NAFLD patients\[[@B1]\]. It was thought that hepatic fatty change was a kind of benign lesions previously. However, the recent research showed that about 10%-30% of NAFLD could evolve into NASH, accompanying by fibrosis, cirrhosis, liver failure and even hepatocellular carcinoma\[[@B2]\]. NAFLD patients are more likely to be accompanied with obesity, diabetes, cardiovascular and cerebrovascular diseases to increase death and disability rate. Owing to the high morbidity rate of obesity and metabolic syndrome worldwide, NAFLD has become the leading cause of chronic liver disease\[[@B1]\]. It is time to identify and evaluate the high citation articles to get insight into history and current situation of NAFLD research.

Citation rank list has been often used in medicine to characterize works with the remarkable intellectual influence\[[@B3]\]. Many highly cited articles have stimulated further standard-breaking investigations and discussions\[[@B4]\]. However, the bibliometric analysis of the most influential articles in NAFLD field remains unexploited. As the most frequently used source database for a broad review of scientific value in a specific research field, Science Citation Index-Expanded (SCI-Expanded) from Thomson Reuters is a highly effective research tool for evaluating scientific performance and tracking evolution trends. In this study, bibliometric method was applied to analyze the citation times, publication year, countries and institutes, journals, subspecialty, and key words of the 100 most cited articles in NAFLD field in SCI-Expanded from 1965 to 2015.

MATERIALS AND METHODS
=====================

The data were obtained from the SCI-Expanded from the Institute for Scientific Information, which indexed 8618 major journals with citation references across 176 categories in science edition in 2015. The keywords for bibliography retrieval in database consisted of "nonalcoholic steatohepatitis", "nonalcoholic fatty liver disease", and their heteromorphic form and abbreviation limited in liver or hepatology fields. Papers were listed according to their citation times from the most to the least. Only the top 100 original articles from the most citation list were included for further analysis. The retrieve process of the top 100 citied articles was shown in Figure [1](#F1){ref-type="fig"}. In detail, the retrieved data for statistical process were imported to Excel 2010. According to JCR in 2014 (available in June 2015), the reported impact factor (IF) of each journal was referred. The 100 top cited articles were assessed by decreasing orders of articles and citation. Bibliometric parameters including publication productions of countries and institutes with five indexes including total, independent, collaborative, first author, and corresponding author articles; distribution of journals and subspecialties; top 10 of most cited articles were assessed.
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Furthermore, the most frequent key words and concepts were also discussed. Part of concepts such as "NAFLD" and "NASH" were abandoned since they completely overlap with the study content. Highly related concepts including all concepts from the Gene Ontology (GO) and the Medical Subject Headings (MeSH) were categorized by semantic search technology using GoPubMed^®^ search engine (<http://www.gopubmed.org/web/gopubmed/>).

RESULTS
=======

Publication year
----------------

After screening, 8828 meaningful articles related to NAFLD were retrieved in the period of 1965 to 2015. It can be seen that the number of total articles increased at an exponential rate, which entered an exponential growth phase since 2004 (Figure [2](#F2){ref-type="fig"}). A power exponential function can describe the growth curve: *Y* = 1 × 10^-233^e^0.2701x^, *R*^2^ = 0.9668.
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The publication years of the top 100 cited articles in NAFLD field spanned from 1980 to 2012 with a citation ranging from 227 to 2151 times since publication. The majority of top 100 cited articles (74%) were concentrated in the 2000s (Figure [3](#F3){ref-type="fig"}). The most cited article published by Kleiner DE (National Cancer Institute, United States) in 2005 was cited 2151 times according to the SCI-Expanded database (Table [1](#T1){ref-type="table"}).

###### 

The information of top 100 cited articles in nonalcoholic fatty liver disease

  **Rank**   **Title of article**                                                                                                                                                                **Journal**                              **First author/institute**                                             **Year**   **Times cited**
  ---------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------- ---------------------------------------------------------------------- ---------- -----------------
  1          Design and validation of a histological scoring system for nonalcoholic fatty liver disease                                                                                         *Hepatology*                             Kleiner DE/NCI, United States                                          2005       2151
  2          Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions                                                                                           *Am J Gastroenterol*                     Brunt EM/Saint Louis University, United States                         1999       1609
  3          Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity                                                                                                  *Gastroenterology*                       Matteoni CA/Cleveland Clin Fdn, United States                          1999       1506
  4          Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity                                                                                    *Hepatology*                             Browning JD/Univ Texas, United States                                  2004       1320
  5          Non-alcoholic steatohepatitis - Mayo-Clinic experiences with A hitherto unnamed disease                                                                                             *Mayo Clin Proc*                         Ludwig J/Mayo Clin, United States                                      1980       1206
  6          Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome                                                                                                               *Hepatology*                             Marchesini G/Università di Bologna, Bologna, Italy                     2003       1134
  7          Nonalcoholic fatty liver disease - a feature of the metabolic syndrome                                                                                                              *Diabetes*                               Marchesini G/Univ Bologna, Italy                                       2001       1072
  8          The natural history of nonalcoholic fatty liver disease: A population-based cohort study                                                                                            *Gastroenterology*                       Adams LA/Mayo Clin, United States                                      2005       974
  9          Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities                                                                                     *Gastroenterology*                       Sanyal AJ/Virginia Commonwealth Univ, United States                    2001       935
  10         The natural-history of nonalcoholic steatohepatitis - a follow-up-study of 42 patients for up to 21 yr                                                                              *Hepatology*                             Powell EE/University of Queensland, Australia                          1990       864
  11         Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis                                                                                              *Hepatology*                             Angulo P/Mayo Clin, United States                                      1999       802
  12         Sources of fatty acids stored in liver and secreted *via* lipoproteins in patients with nonalcoholic fatty liver disease                                                            *J Clin Invest*                          Donnelly KL/Univ Minnesota, United States                              2005       801
  13         Nonalcoholic steatohepatitis - an expanded clinical entity                                                                                                                          *Gastroenterology*                       Bacon BR/St. Louis UNIV, United States                                 1994       756
  14         Association of nonalcoholic fatty liver disease with insulin resistance                                                                                                             *Am J Med*                               Marchesini G/Univ Bologna, United States                               1999       736
  15         Long-term follow-up of patients with NAFLD and elevated liver enzymes                                                                                                               *Hepatology*                             Ekstedt M/Linkoping Univ Hosp, Sweden                                  2006       719
  16         Expanding the natural history from cryptogenic cirrhosis to of nonalcoholic steatohepatitis: Hepatocellular carcinoma                                                               *Gastroenterology*                       Bugianesi E/Univ Turin, Italy                                          2002       712
  17         The utility of radiological imaging in nonalcoholic fatty liver disease                                                                                                             *Gastroenterology*                       Saadeh S/Inova Fairfax Hosp, United States                             2002       708
  18         The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice                                                                              *J Clin Invest*                          Xu AM/Univ Auckland, China                                             2003       696
  19         Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese                                                               *Gastroenterology*                       Dixon JB/Monash Univ, Australia                                        2001       666
  20         A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis                                                                                            *N Engl J Med*                           Belfort R/Univ Texas, Italy                                            2006       662
  21         Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease                                                                                              *Nature Genet*                           Romeo S/Univ Texas, United States                                      2008       614
  22         NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome                                                                   *Hepatology*                             Chitturi S/Univ Sydney, Australia                                      2002       610
  23         Sampling variability of liver biopsy in nonalcoholic fatty liver disease                                                                                                            *Gastroenterology*                       Ratziu V/Grp Hosp Pitie Salpetriere, France                            2005       572
  24         Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men               *J Clin Endocrinol Metab*                Seppala-Lindroos A/Univ Helsinki, Finland                              2002       563
  25         Beyond insulin resistance in NASH: TNF-alpha or adiponectin?                                                                                                                        *Hepatology*                             Hui JM/Westmead Hosp, Australia                                        2004       552
  26         Magnetic resonance spectroscopy to measure hepatic triglyceride content: Prevalence of hepatic steatosis in the general population                                                  *Am J Physiol -Endocrinol Metab*         Szczepaniak, LS/Univ Texas, United States                              2005       551
  27         Pioglitazone, Vitamin E or Placebo for Nonalcoholic Steatohepatitis                                                                                                                 *N Engl J Med*                           Sanyal AJ/Virginia Commonwealth Univ, United States                    2010       550
  28         The natural history of nonalcoholic fatty liver: A follow-up study                                                                                                                  *Hepatology*                             Teli MR/Univ Newcastle, United Kingdom                                 1995       544
  29         Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease                                                                                                        *J. Biol. Chem*.                         Samuel VT/Yale Univ, Australia                                         2004       537
  30         Obesity increases sensitivity to endotoxin liver injury: Implications for the pathogenesis of steatohepatitis                                                                       *Proc Natl Acad Sci USA*                 Yang SQ/Johns Hopkins Univ, United States                              1997       504
  31         Prevalence of fatty liver in children and adolescents                                                                                                                               *Pediatrics*                             Schwimmer JB/Univ Calif San Diego, United States                       2006       454
  32         Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma                                                                                                   *Gastroenterology*                       El-Serag HB/Houston Dept Vet Affairs Med Ctr, United States            2004       452
  33         Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis                                                                                *Gastroenterology*                       Feldstein AE/Mayo Clin, United States                                  2003       451
  34         Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos Nutrition and Liver Study                                                                         *Hepatology*                             Bedogni G/Fondo Studio Malattie Fegato ONLUS, Italy                    2005       449
  35         CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis                                                                                  *J Clin Invest*                          Leclercq IA/Univ Sydney, United States                                 2000       435
  36         Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease                                                                         *Hepatology*                             Li ZP/Johns Hopkins Univ, United States                                2003       433
  37         Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis                                                                          *Gastroenterology*                       George DK/Royal Brisbane Hosp, Australia                               1998       431
  38         Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values                                                                              *Hepatology*                             Mofrad P/Virginia Commonwealth Univ, U United States                   2003       427
  39         The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD                                                                                *Hepatology*                             Angulo P/Mayo Clin, United Kingdom                                     2007       425
  40         A pilot study of ploglitazone treatment for nonalcoholic steatohepatitis                                                                                                            *Hepatology*                             Promrat K/NIDDK, United States                                         2004       410
  41         Improved nonalcoholic steatohepatitis after 48 wk of treatment with the PPAR-gamma ligand rosiglitazone                                                                             *Hepatology*                             Neuschwander-Tetri BA/St. Louis Univ, United States                    2003       406
  42         Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity                                                                                                          *Nature*                                 Henao-Mejia J/Yale Univ, United States                                 2012       399
  43         Liver pathology and the metabolic syndrome X in severe obesity                                                                                                                      *J Clin Endocrinol Metab*                Marceau P/SUNY Hlth Sci Ctr, Canada                                    1999       389
  44         The metabolic syndrome as a predictor of nonalcoholic fatty liver disease                                                                                                           *Ann Intern Med*                         Hamaguchi M/Asahi Univ, Japan                                          2005       387
  45         Metformin in non-alcoholic steatohepatitis                                                                                                                                          *Lancet*                                 Marchesini G/Univ Bologna, Italy                                       2001       376
  46         Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association                                                             *Hepatology*                             Pagano G/Univ Turin, Italy                                             2002       373
  47         Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice                                                                     *Proc Natl Acad Sci USA*                 Dumas ME/Univ London Imperial Coll Sci Technol & Med, United Kingdom   2006       361
  48         Hepatic cytochrome p450 2E1 is increased in patients with nonalcoholic steatohepatitis                                                                                              *Hepatology*                             Weltman MD/Westmead Hosp, Sweden                                       1998       355
  49         The histological course of nonalcoholic fatty liver disease: A longitudinal study of 103 patients with sequential liver biopsies                                                    *J Hepatol*                              Adams LA/Mayo Clin, United States                                      2005       349
  50         Nonalcoholic steatohepatitis - A study of 49 patients                                                                                                                               *Hum Pathol*                             Lee RG/Oregon Health Sciences University, United States                1989       346
  51         Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study   *Gastroenterology*                       Williams CD/Brooke Army Med Ctr, United States                         2011       343
  52         Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression *via* a lysosomal pathway                                                                         *Hepatology*                             Feldstein AE/Mayo Clin, United States                                  2004       336
  53         *In vivo* assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease                                                           *Hepatology*                             Wieckowska A/Cleveland Clin Fdn, United States                         2006       330
  54         Therapeutic effects of restricted diet and exercise in obese patients with fatty liver                                                                                              *J Hepatol*                              Ueno T/Kurume University School of Medicine, Japan                     1997       329
  55         Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients                                                             *Hepatology*                             Crespo J/Hosp Univ Marques Valdecilla, Spain                           2001       327
  56         Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis                              *Hepatology*                             Yamaguchi K/Duke Univ, United States                                   2007       324
  57         Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss                                                                                       *Hepatology*                             Dixon JB/Monash Univ, Australia                                        2004       324
  58         The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis     *Gut*                                    Wigg AJ/Queen Elizabeth Hosp, Australia                                2001       324
  59         Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity                                                                                               *Proc Natl Acad Sci USA*                 Fabbrini E/Washington Univ, Greece                                     2009       323
  60         Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study                                                                           *Hepatology*                             Laurin J/Mayo Clin, United States                                      1996       317
  61         Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study                                                                                                      *J Pediatr*                              Lavine JE/Univ Calif San Diego, United States                          2000       312
  62         A randomized controlled trial of metformin *vs* vitamin E or prescriptive diet in nonalcoholic fatty liver disease                                                                  *Am J Gastroenterol*                     Bugianesi E/Univ Bologna, Italy                                        2005       309
  63         Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial                                                                                   *Hepatology*                             Lindor KD/Mayo Clin, Canada                                            2004       305
  64         Deletion of NEMO/IKK gamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma                                                                           *Cancer Cell*                            Luedde T/Univ Cologne, Belgium                                         2007       285
  65         NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States                                                                       *Hepatology*                             Marrero JA/Univ Michigan, United States                                2002       283
  66         Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis                                                                                   *Am J Gastroenterol*                     Harrison SA/Univ Texas, United States                                  2003       281
  67         High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: A potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis   *Hepatology*                             Paradis V/Hop Bicetre, France                                          2001       281
  68         Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case-control study                                                                                     *Hepatology*                             Poonawala A/Johns Hopkins Univ, United States                          2000       281
  69         Insulin resistance-associated hepatic iron overload                                                                                                                                 *Gastroenterology*                       Mendler MH/Hop Pontchaillou, France                                    1999       281
  70         Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis                                                                                                                      *J Biol Chem*                            Malhi H/Mayo Clin, United States                                       2006       280
  71         Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis                                                                   *Hepatology*                             Musso G/Univ Turin, Italy                                              2003       279
  72         Cytokines and NASH: A pilot study of the effects of lifestyle modification and vitamin E                                                                                            *Hepatology*                             Kugelmas M/Univ Louisville, United States                              2003       275
  73         Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients                                                                            *Diabetes*                               Targher G/Osped Sacro Cuore don G Calabria, Italy                      2005       271
  74         A lipidomic analysis of nonalcoholic fatty liver disease                                                                                                                            *Hepatology*                             Puri P/Virginia Commonwealth Univ, United States                       2007       269
  75         The Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Nonalcoholic Steatohepatitis                                                                            *Hepatology*                             Ascha MS/Cleveland Clin, United States                                 2010       268
  76         Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients                                                       *Diabetes Care*                          Targher G/Osped Sacro Cuore don Calabria, United Kingdom               2007       268
  77         Burden of liver disease in the United States: Summary of a workshop                                                                                                                 *Hepatology*                             Kim WR/Mayo Clin, United States                                        2002       266
  78         Plasma Endotoxin Concentrations In Patients With Alcoholic And Nonalcoholic Liver-Disease - Reevaluation With An Improved Chromogenic Assay                                         *J Hepatol*                              Fukui H/ROBERT BOSCH KRANKENHAUS, Germany                              1991       264
  79         Histopathology of pediatric nonalcoholic fatty liver disease                                                                                                                        *Hepatology*                             Schwinnner JB/Univ Calif San Diego, USA                                2005       262
  80         A position statement on NAFLD/NASH based on the EASL 2009 special conference                                                                                                        *J Hepatol*                              Ratziu V/Azienda USL Modena, Italy                                     2010       259
  81         Increased intestinal permeability in obese mice: New evidence in the pathogenesis of nonalcoholic steatohepatitis                                                                   *Am J Physiol-Gastroint Liver Physiol*   Brun P/Univ Padua, Italy                                               2007       258
  82         Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease                                                                                         *Hepatology*                             Villanova N/Alma Mater Studiorum Univ Bologna, Italy                   2005       258
  83         Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis                                                                                     *Hepatology*                             Perez-Carreras M/Hosp Univ 12 Octubre, Spain                           2003       254
  84         Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis                                                                                      *Hepatology*                             Ratziu V/Hop La Pitie Salpetriere, France                              2002       254
  85         A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis                                                                                                 *Am J Gastroenterol*                     Caldwell SH/Univ Virginia, United States                               2001       247
  86         Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas                                                                                        *J Clin Invest*                          Horie Y/Akita Univ, Japan                                              2004       240
  87         Randomized Controlled Trial Testing the Effects of Weight Loss on Nonalcoholic Steatohepatitis                                                                                      *Hepatology*                             Promrat K/Brown Univ, United States                                    2010       239
  88         Insulin resistance in chronic hepatitis C: Association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis                                                              *Gastroenterology*                       Moucari R/Hop Beaujon, France                                          2008       239
  89         Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: Results of a pilot study                                                                             *Am J Gastroenterol*                     Abdelmalek MF/Mayo Clin, United States                                 2001       239
  90         Steatosis in chronic hepatitis C: Relative contributions of obesity, diabetes mellitus, and alcohol                                                                                 *Hepatology*                             Monto A/Univ Calif San Francisco, United States                        2002       237
  91         Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis                                                                         *Hepatology*                             Yokohama S/Dokkyo Univ, Japan                                          2004       235
  92         Hepatic-Effects Of Dietary Weight-Loss In Morbidly Obese Subjects                                                                                                                   *J Hepatol*                              Andersen T/Univ Copenhagen, Denmark                                    1991       236
  93         Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy trial                      *Gastroenterology*                       Ratziu V/Univ Paris, France                                            2008       234
  94         Diagnosis of Fibrosis and Cirrhosis Using Liver Stiffness Measurement in Nonalcoholic Fatty Liver Disease                                                                           *Hepatology*                             Wong VWS/Hop Haut Leveque, China                                       2010       232
  95         Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation                                                                            *Gastroenterology*                       Weltman MD/Univ Sydney, Australia                                      1996       230
  96         Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases                                                  *J Am Coll Surg*                         Fernandez FG/Washington Univ, United States                            2005       229
  97         Adiponectin and its receptors in non-alcoholic steatohepatitis                                                                                                                      *Gut*                                    Kaser S/Univ Innsbruck Hosp, Spain                                     2005       229
  98         Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C                                                                                           *Hepatology*                             Hui JM/Univ Sydney, Australia                                          2003       229
  99         Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European liver fibrosis panel and exploring simple markers                                      *Hepatology*                             Guha IN/Guha, United Kingdom                                           2008       228
  100        Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity                                      *J Clin Endocrinol Metab*                Bugianesi E/Univ Turin, Italy                                          2005       227

NAFLD: Nonalcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis; TNF: Tumor necrosis factor; ALT: Alanine aminotransferase; PPAR: Peroxisome proliferator activated receptor; HCV: Hepatitis C virus.
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Publication distribution of countries and institutes
----------------------------------------------------

The top 100 cited articles were originated from 19 countries. The most productive country was the United States (55), followed sequentially by Italy (20), Australia (14), France (9), United Kingdom (7). The rest of the countries had less than four publications (Table [2](#T2){ref-type="table"}). The numbers in the brackets refer to the publication number (similarly hereinafter).

###### 

Countries of origin of the top 100 articles in nonalcoholic fatty liver disease

  **Rank**   **Nation**       **TP**   **FP**   **SP**   **CP**   **RP**   **TC**
  ---------- ---------------- -------- -------- -------- -------- -------- --------
  1          United States    55       48       45       10       49       26975
  2          Italy            20       13       11       9        15       5567
  3          Australia        14       10       8        6        9        4767
  4          France           9        6        6        3        7        1861
  5          United Kingdom   7        5        2        5        2        1826
  6          Japan            4        4        4        0        4        1191
  7          Spain            3        3        2        1        2        810
  8          Sweden           2        2        1        1        1        1074
  9          China            2        2        0        2        0        928
  10         Canada           2        2        0        2        0        694
  11         Germany          2        1        1        1        1        264
  12         Finland          1        1        1        0        1        563
  13         Greece           1        1        0        1        0        323
  14         Belgium          1        1        0        1        0        285
  15         Denmark          1        1        1        0        1        236
  16         New Zealand      1        0        0        1        1        0
  17         Austria          1        0        0        1        1        0
  18         South Africa     1        0        0        1        0        0

TP: The number of total 100 top-cited articles; FP: The number of first author articles; SP: The number of single-country articles; CP: The number of internationally collaborative articles; RP: The number of corresponding author articles in total 100 top-cited articles; TC: Total citation of first author articles; Rank: According to the order of TP firstly and TC secondly. As for New Zealand Austria and South Africa, the country with more citation of corresponding author articles took precedence.

Twelve institutions published more than 4 top cited articles. Mayo Clin (12) ranked the first place in NAFLD research, followed by University of Bologna (9), University of Turin (9), The University of Sydney (7) and University of California, San Diego (6). And the rest of the Institutes such as University of Texas, Saint Louis University and Virginia Commonwealth University contributed five each to the top 100 cited articles (Table [3](#T3){ref-type="table"}).

###### 

Top productive institutions list with top 100 cited articles in nonalcoholic fatty liver disease

  **Rank**   **Institution**                           **TP**   **FP**   **SP**   **CP**   **RP**   **TC**
  ---------- ----------------------------------------- -------- -------- -------- -------- -------- --------
  1          Mayo Clinic                               12       12       8        4        11       5950
  2          University of Bologna                     9        5        1        8        5        3627
  2          University of Turin                       9        4        1        8        4        1591
  4          The University of Sydney                  7        4        1        6        2        1504
  5          University of California, San Diego       6        3        0        6        3        1028
  6          University of Texas                       5        5        1        4        4        3428
  7          Saint Louis University                    5        3        3        2        3        2771
  8          Virginia Commonwealth University          5        4        2        3        2        2181
  9          Westmead Hospital                         4        2        0        4        3        907
  10         Washington University                     4        2        0        4        1        552
  11         University of Paris                       4        1        0        4        1        234
  12         University of California, San Francisco   4        1        1        3        0        237
  13         National Cancer Institute                 4        1        0        4        1        2151
  14         MetroHealth Medical Center                4        0        0        4        0        0

TP: The number of total 100 top-cited articles; TP: The number of total 100 top-cited articles; FP: The number of first author articles; SP: The number of single-country articles; CP: The number of internationally collaborative articles; RP: The number of corresponding author articles in total 100 top-cited articles; TC: Total citation of first author articles; Rank: According to the order of TP firstly and TC secondly. As for National Cancer Institute and Metrohlth Med Ctr, the institute with more corresponding author articles took precedence.

Subspecialties and journals
---------------------------

According to the JCR in 2014, the top 100 articles of NAFLD were scattered in 13 SCI subject categories (Table [4](#T4){ref-type="table"}). These main subspecialties were Gastroenterology and Hepatology (71), Endocrinology and Metabolism (7), General and Internal Medicine (6), Research and Experimental Medicine (4) and Science and Technology (4).

###### 

Most frequent subspecialties with the top 100 cited articles in nonalcoholic fatty liver disease

  **Rank**   **Subject categories**               **No. of articles**   **Total citation**
  ---------- ------------------------------------ --------------------- --------------------
  1          Gastroenterology and Hepatology      71                    33290
  2          Endocrinology and Metabolism         7                     3341
  3          General and Internal Medicine        6                     3917
  4          Research and Experimental Medicine   4                     2172
  5          Science and Technology               4                     1587
  6          Biochemistry and Molecular Biology   2                     817
  7          Physiology                           2                     809
  8          Pediatrics                           2                     766
  9          Genetics and Heredity                1                     614
  10         Pathology                            1                     346
  11         Cell Biology                         1                     285
  12         Oncology                             1                     285
  13         Surgery                              1                     229

Remarks: In the situation of equal numbers of articles, the subspecialties with more total citation took precedence.

The top 100 articles were distributed in 25 journals including professional journals and other disciplines journals. Eleven (44%) journals published 2 or more articles (Table [5](#T5){ref-type="table"}), among which the most productive journal was *Hepatology* (42), followed by *Gastroenterology* (16), *Am J Gastroenterol* (5), *J Hepatol* (5), *J Clin Invest* (4), *Proc Natl Acad Sci USA* (3) and *J Clin Endocrinol Metab* (3).

###### 

Journal distribution of top 100 cited articles in nonalcoholic fatty liver disease

  **Rank**   **Journal**                 **No. of articles**   **Total citation**   **Impact factor (2014)**
  ---------- --------------------------- --------------------- -------------------- --------------------------
  1          *Hepatology*                42                    18867                11.055
  2          *Gastroenterology*          16                    9490                 16.716
  3          *Am J Gastroenterol*        5                     2685                 10.755
  3          *J Hepatol*                 5                     1437                 11.336
  5          *J Clin Invest*             4                     2172                 13.215
  6          *Proc Natl Acad Sci USA*    3                     1188                 9.674
  7          *J Clin Endocrinol Metab*   3                     1179                 3.457
  8          *Diabetes*                  2                     1343                 8.095
  9          *New Engl J Med*            2                     1212                 55.873
  10         *J Biol Chem*               2                     817                  4.573
  11         *Gut*                       2                     553                  14.66

Remarks: In the situation of equal numbers of articles, the journals with more total citation took precedence.

The most frequently cited articles
----------------------------------

As elaboration of all the top 100 cited articles is difficult, the top 10 citation articles were further discussed instead. United States (7), Italy (2) and Australia (1) respectively published the top 10 most frequently cited articles (Table [1](#T1){ref-type="table"}). Three in ten focused on epidemiological subjects to investigate the regional and ethnic differences and explore the genetic mechanism implied in NAFLD, which were published respectively in the year of 1990 (864 citations), 2004 (1320 citations) and 2005 (974 citations) (Table [1](#T1){ref-type="table"}). Other three articles discussed the pathogenic role of metabolic syndrome where insulin resistance and obesity were repeatedly mentioned. The rest of articles analyzed NAFLD from the clinical and histological aspect, among which two were about the histological grading and staging of NAFLD.

Highly related concepts
-----------------------

Highly related concepts of the top 100 cited papers from GO and MeSH with frequency more than 10 times were listed in Table [6](#T6){ref-type="table"}. The analysis indicated that multisystem metabolic syndrome and its related key words (obesity, insulin resistance, *etc*.) occupied a majority of proportion. Some key words discussed histological and pathology characteristics of NAFLD including hepatic steatosis, fibrosis, biopsies, *etc*. Noteworthy, the topic of epidemiology covering prevalence, male/men, female/women, middle aged and adolescent was also involved in frequent concepts (Table [7](#T7){ref-type="table"}).

###### 

High frequency key words in the top 100 cited articles in nonalcoholic fatty liver disease (frequency \> 2)

  **Rank**   **Key word**          **Frequency**
  ---------- --------------------- ---------------
  1          Hepatic steatosis     4
  1          Obesity               4
  3          Fibrosis              3
  4          Metabolic syndrome    2
  4          Insulin resistance    2
  4          Biopsies              2
  4          Intestinal bacteria   2
  4          Endotoxin             2

###### 

Highly related concepts of the top 100 articles in nonalcoholic fatty liver disease categorized by GoPubMed® search engine

  **Rank**   **Highly related concepts**     **Frequency**   **Rank**   **Highly related concepts**   **Frequency**
  ---------- ------------------------------- --------------- ---------- ----------------------------- ---------------
  1          Fatty liver                     97              24         Wounds and injuries           15
  2          Male                            91              25         Aspartate Aminotransferases   14
  3          Humans                          89              26         Mice                          14
  4          Female                          84              27         Carcinoma, Hepatocellular     13
  5          Middle aged                     72              28         Tumor necrosis factor-alpha   12
  6          Patients                        71              29         Multivariate analysis         12
  7          Fibrosis                        59              30         Prospective studies           12
  8          Biopsy                          45              31         Follow-up studies             12
  9          Liver                           45              32         Hepatitis C                   11
  10         Obesity                         42              33         cell killing                  11
  11         Aged                            36              34         cytolysis                     11
  12         Insulin                         35              35         Medicalization                11
  13         Serum                           32              36         Metabolic syndrome X          10
  14         Body mass index                 31              37         Fatty acids, nonesterified    10
  15         Syndrome                        25              38         Aspartic acid                 10
  16         Risk Factors                    24              39         Hypoglycemic agents           10
  17         Alanine transaminase            23              40         Homeostasis                   10
  18         Alanine transaminase activity   19              41         Severity of illness index     10
  19         Pathogenesis                    19              42         Men                           10
  20         Prevalence                      18              43         Personal autonomy             10
  21         Hepatocytes                     17              44         Women                         10
  22         Alanine                         16              45         Adolescent                    10
  23         Triglycerides                   15                                                       

DISCUSSION
==========

This paper used bibliometrics method to evaluate top 100 cited articles to reveal the global publication performance of NAFLD. The high citation articles can reflect the development evolution direction and scientific level in the NADLD research field to a certain extent.

Publication trends and distribution of NAFLD-related literature
---------------------------------------------------------------

In recent five decades, exponential increase of published articles reflects the globally development trend of NAFLD. In line with the increased prevalence of obesity, diabetes, and hyperlipemia, NAFLD has been increasing worldwide over recent half century\[[@B5]\]. As a result of modern sedentary and over-nutrition lifestyle which makes a very large population fall risk of NAFLD, research on NAFLD would develop more rapidly in the near future\[[@B6]\].

East Asian countries/territories such as Japan, China (mainland), South Korea and Taiwan occupied an important place in NAFLD research and their importance tended to be more and more obvious. This might owe to the rising prevalence of NAFLD in Asia recently as well as the growth of economic power and the advance of scientific research which prompted these countries/territories to invest more in research to prevent and control NAFLD\[[@B6]\]. A global scientific review covered total articles relevant to NAFLD from 1986 to 2013 were performed to analyze distribution of publication number and found that Japan, China (mainland) and South Korea ranked second, fourth and ninth respectively among the most productive country/territories\[[@B7]\]. However, only six of top 100 cited papers originate these countries/territories. It shows that the quality and influence of research in NAFLD need to improve for East Asian countries.

It was found that most of the 100 most cited papers were published in 2000s (74 articles), while the most of high citation times per articles distributed in 1990s. These distributions suggested that the older paper had the more citation times\[[@B8]\]. The opinions in 1990s and 2000s were neither too old to be outdated nor too nearly to be cited. Actually, academic community has recognized that the real importance and influence of a work often can't be precisely assessed for at least 2 decades after it is published\[[@B9]\].

The research hotspots of NAFLD
------------------------------

Highly related concepts and top keywords could partly reflect the profile of hotspots in NAFLD research. GoPubMed^®^ search engine connect text (abstracts from the MEDLINE database) to background knowledge in the form of semantic networks of concept categories, which is done by meaning and not by keywords only. These results are approximately consistent with our contemporaneous bibliometric analysis in high frequency keywords that covered total articles relevant to NAFLD\[[@B7]\].

**Potential pathogenesis:** According to highly related concepts list, a cluster of pathogenesis related keywords occupied a majority of high frequency words mentioned by NAFLD researches. The research hotspots extracted using bibliometrics analysis informs the underlying pathogenesis of NAFLD. The results indicated that multisystem metabolic syndrome and its combination of symptoms including insulin resistance, obesity as well as oxidative stress and dyslipoproteinemia played a vital role in the pathogenesis of NAFLD. In fact, although pathogenesis of NAFLD remains elusive, the severity of NAFLD seems to increase in parallel with the features of metabolic syndrome\[[@B10]-[@B12]\]. NAFLD/NASH is increasingly regarded as a hepatic manifestation of metabolic syndrome. However, considering that not all patients with NAFLD/NASH suffer from one of these conditions\[[@B1]\], still uncertain pathogenesis of NAFLD might hinder the people and needs to be explored\[[@B13]\].

**Epidemic studies:** Concepts related to epidemiology such as humans, male/men, female/women, middle aged and adolescent make up another high frequency concepts cluster, which might be closely involved in the accelerating incidence of this disease. The morbidity rate of NAFLD has doubled during last 20 years, whereas the morbidity rate of other chronic liver diseases has remained stable or even decreased. Epidemic investigations of NAFLD primarily focus on human genetic and metabolic studies\[[@B14]\]. Several epidemiological investigations such as case series, familial and twin studies have widely revealed the function of heritability\[[@B15]\]. Noteworthy, in comparison to high-risk population of NAFLD clustering around middle-aged and elderly adults before, younger age trend has gradually shown especially in Asian countries during the last two decades. Following the epidemics of childhood obesity, NAFLD as the most common form of chronic liver disease in adolescents has become a reality\[[@B16]\].

**Medicalization progress:** Medicalization is also a high frequency concepts cluster. Lack of uniformed diagnosis regulation and no established therapy remains a hindrance to be broken through in this field. NASH is characterized by hepatocellular damage, lobular necroinflammation and fibrogenesis. The early diagnosis of advanced fibrosis in NAFLD is therefore crucial\[[@B17],[@B18]\]. The liver biopsy remains the most reliable diagnostic method to appropriately evaluate the severity of liver fibrosis. Facing to limitations of this invasive technique in current use, a number of experimental biomarkers have been developed in order to predict the degree of liver fibrosis\[[@B19]\]. Moreover, as a promising method for evaluation of patients with NAFLD, nuclear medicine through liver scintigraphy has recently been proposed\[[@B20]\].

Preventing existing comorbidities such as metabolic disorders, cardiovascular or cerebrovascular events are the primary target for NAFLD treatment, while the secondary goal of NAFLD therapy is reversal of hepatic steatosis\[[@B21]-[@B23]\]. Lifestyle modification such as weight loss and balanced diet remains the main way of management in NAFLD/NASH. In addition, the benefit of nutritional supplementation on disease progression has attracted growing interest\[[@B24]\]. Most recent data has evidenced the effects of nutrients and dietary bioactive compounds intake (*i.e*., long-chain PUFA, Vitamin E, Vitamin D, minerals and polyphenols) on the modulation of molecular mechanisms leading to fat accumulation, oxidative stress, inflammation and liver fibrosis in NAFLD patients\[[@B25]\]. In the field of pharmaceutical therapies, a wide range of drugs have been applied in clinical trials, including antioxidants, lipid lowering agents, and rennin-angiotensin system blockers\[[@B26]-[@B28]\]. Up to the present, lifestyle modification is the main clinical recommendation as an initial step. Although promising results have shown that long-term insulin sensitizers such as metformin, rosiglitazone, and thiazolidinediones are effective in NAFLD therapy, there are no approved drugs\[[@B29]-[@B31]\].

In conclusion, it is important to acknowledge the top 100 cited articles because they marked with the leading countries, institutions, journals, hotspots, past and current trends in NAFLD field that could provide the foundation for further investigations. Highly related concepts of the top 100 cited papers in NAFLD suggest that pathogenesis mainly related to metabolic syndrome, epidemiology, and medicalization including diagnosis and treatment are attracting ever-growing attention.
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COMMENTS
========

Background
----------

Due to the increasing prevalence of obesity and metabolic syndrome worldwide, nonalcoholic fatty liver disease (NAFLD) becomes the leading cause of chronic liver disease. The rapid growth of NAFLD research recently drives top cited articles in the field to be identified and bibliometric analysis to assess the history and current situation, publication distribution of leading countries and institutes as well as the research hotspots of NAFLD.

Research frontiers
------------------

A systematic review in 2015 covered total articles relevant to NAFLD from Science Citation Index-Expanded (SCI-Expanded) showed article amount has appeared to geometric growth in recent decades. However, bibliometric result from total articles is not sufficient to indicate the evolution and direction in NAFLD research. The citation times by other authors has been used as a measurable comparison to evaluate the academic impact of an article in its subject field. To date, there have no top cited articles analysis were carried out in NAFLD field.

Innovations and breakthroughs
-----------------------------

This paper summarized the current findings from the analysis of the top 100 cited articles in NAFLD field. It is the first global look at the history and current situation of NAFLD research to assess the performances of leading countries/territories and institutes and research hotspots of this disease. In terms of the number of published 100 top-cited articles in NAFLD, United States was the most predominant country and Mayo Clin was the most productive institution. Highly related concepts of the top 100 cited papers in NAFLD suggest that pathogenesis (mainly related to metabolic syndrome), epidemiology, and medicalization (including diagnosis and treatment) are attracting ever-growing attention.

Applications
------------

Top 100 cited articles marked with the leading countries, institutions, journals, hotspots, past and current trends in NAFLD field that could provide the foundation for further investigations. Medical bibliometric analysis on top 100 cited articles is expected to provide a reference for the researchers to get involved in NAFLD area.

Terminology
-----------

The articles involved in bibliometric analysis were collected based on online version of SCI-Expanded from Thomson Reuters. Keywords for bibliography retrieval in database consisted of "nonalcoholic steatohepatitis" and "nonalcoholic fatty liver disease".

Peer-review
-----------

This study retrieved the top 100 cited articles in the field of NAFLD and determined the country of origin, peak of highly-cited articles and international collaborations. The present study is very interesting on a high prevalent chronic liver disease.
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